Filing Flows › Iradimed (IRMD) › Q4 2025
Iradimed (IRMD) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 6, 2026
Iradimed (IRMD) reported revenue of $22.7M for the fourth quarter 2025 (Q4 2025), +17% from a year earlier and +7% from the quarter before. Operating margin was 31.3%, net earnings $6.4M (28.4% of revenue).
Iradimed, Q4 2025: revenue $22.7M (+17% year over year), operating margin 31.3%, net earnings $6.4M, operating cash flow $5.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.7M | +7% | +17% |
| Gross profit | $17.0M | +3% | +15% |
| Operating profit | $7.1M | +4% | +22% |
| Net earnings | $6.4M | +16% | +25% |
| Operating cash flow | $5.9M | -15% | -1% |
| Free cash flow | $5.5M | — | +88% |
What changed
Revenue was $22.7M in Q4 2025, up 17% year over year and up 7% from the previous quarter.
Gross margin was 75.1%, down 1.1 points from a year earlier. Operating profit was $7.1M, a 31.3% margin (up 1.3 points year over year). Of the extra revenue versus a year earlier, 39% reached operating profit, above the 30% margin then. Operating expenses grew 11% against revenue growth of 17%. The fastest-growing cost line was Research & development (+40%). Net earnings were $6.4M, up 25% year over year. The effective tax rate was 17.3%.
Operating cash flow was $5.9M (down 1% year over year), 92% of net earnings. Non-cash charges added back $381K of depreciation and amortization and $696K of share-based compensation. Working capital and other items used $1.6M. After capital Expenditures ($417K), free cash flow as the company reports it was $5.5M.
Questions
What was Iradimed's revenue in the fourth quarter 2025?
Iradimed (IRMD) reported revenue of $22.7M for the fourth quarter 2025 (Q4 2025), +17% from a year earlier and +7% from the quarter before.
Was Iradimed profitable in the fourth quarter 2025?
Operating profit was $7.1M (31.3% of revenue) and net earnings $6.4M.
Source: Iradimed 10-K on SEC EDGAR.